> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Umicore Argentina CGMP Deviations
- URL: https://www.fdaweb.com/umicore-argentina-cgmp-deviations/
- Published: 2026-11-17T20:52:22.000Z
- Updated: 2026-11-17T20:52:22.000Z
- Author: David McFarland
- Tags: enforcement

A 6/4-6/8 FDA inspection at the Umicore Argentina drug manufacturing facility in Buenos Aires, Argentina, found significant deviations from current good manufacturing practice (CGMP) regulations for active pharmaceutical ingredients (APIs). An 11/6 [Warning Letter](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/umicore-argentina-sa-736869-11062026?ref=fdaweb.com) says the specific deviations were:

- failure to adequately investigate and document out-of-specification results and implement appropriate corrective actions; and
- failure to properly maintain equipment, buildings, and facilities used in the manufacture of APIs in a clean condition, and failure to clean equipment and utensils to prevent contamination or carry-over of a material that would alter the quality of the API beyond the official or other established specification.

FDA recommends that Umicore engage a qualified consultant to conduct a six-system audit of its entire operation for CGMP compliance, assist it in meeting CGMP requirements, and evaluate the completion and efficacy of its corrective and preventive actions before Umicore pursues resolution of its compliance status with the agency.

Umicore was told to address the deviations without delay and to ensure that adequate resources are allocated to fully address them and prevent their recurrence.